Elanco Animal Health (NYSE:ELAN) Stock Gets Price Target Reduction from Morgan Stanley

by · The Cerbat Gem

Elanco Animal Health (NYSE:ELAN – Free Report) had its target price cut by Morgan Stanley from $26.00 to $25.00 in a research note published on Thursday,Benzinga reports. They currently have an equal weight rating on the stock.

ELAN has been the topic of several other reports. Jefferies Financial Group downgraded Elanco Animal Health from a “buy” rating to a “hold” rating and reduced their target price for the stock from $31.00 to $24.00 in a research report on Tuesday, October 20th. The Goldman Sachs Group assumed coverage on Elanco Animal Health in a research note on Friday, October 16th. They issued a “buy” rating and a $32.00 target price for the company. UBS Group raised their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Finally, Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Get Our Latest Analysis on Elanco Animal Health

Elanco Animal Health Trading Down 0.9%

Shares of ELAN opened at $23.04 on Thursday. The firm has a market capitalization of $11.51 billion, a P/E ratio of -56.20, a PEG ratio of 2.05 and a beta of 1.70. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The firm’s 50-day moving average is $23.13 and its two-hundred day moving average is $23.82. Elanco Animal Health has a twelve month low of $19.40 and a twelve month high of $27.98.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same period in the previous year, the firm posted $0.26 earnings per share. Elanco Animal Health’s revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts predict that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.

Insider Activity

In other Elanco Animal Health news, Director Michael J. Harrington purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were purchased at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares in the company, valued at $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert M. Vanhimbergen purchased 4,200 shares of the business’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $23.08 per share, with a total value of $96,936.00. Following the completion of the acquisition, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. The trade was a 3.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 63,198 shares of company stock valued at $1,473,109 over the last quarter. Insiders own 1.14% of the company’s stock.

Institutional Trading of Elanco Animal Health

Large investors have recently added to or reduced their stakes in the business. Anchor Investment Management LLC acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at about $29,000. Covestor Ltd increased its holdings in Elanco Animal Health by 48.2% in the third quarter. Covestor Ltd now owns 1,383 shares of the company’s stock worth $31,000 after purchasing an additional 450 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in Elanco Animal Health in the second quarter worth approximately $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Elanco Animal Health in the second quarter valued at approximately $38,000. Finally, Root Financial Partners LLC bought a new position in shares of Elanco Animal Health during the 3rd quarter worth approximately $41,000. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

(Get Free Report)

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.

Featured Stories